title: [Does the use of TachoSil allow to reduce the morbidity of axillary dissection?].
abstract: The lymphocele is the most frequently encountered complication after axillary dissection performed for breast cancer (15-81%). This study compares the efficacy of a lympho-hemostatic combipatch TachoSil(®) versus conventional implementation of a suction drain on the incidence and severity of lymphoceles. This is a case (group TachoSil(®)n=20) control (drainage group) n=40 study. In our study, we demonstrated an increased rate of postoperative complications (<3weeks) in the group TachoSil(®) (P=0.0265) explained by a lymphocele rate significantly higher (P=0.0194). However, no significant difference was demonstrated on the severity of these lymphoceles. Beyond 3weeks postoperatively, the two groups were comparable in terms of postoperative complications. The TachoSil(®) does not prevent the formation of seroma but their severity is not increased. In addition, it reduces of more than 48hours the duration of hospitalization stay (P=0.002).
authors: Service de chirurgie et d'oncologie gynécologique, pôle de gynécologie obstétrique, médecine fœtale, médecine et biologie de la reproduction, faculté de médecine de Tours, université François-Rabelais, hôpital Bretonneau, centre hospitalo-universitaire de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 1, France.
authors: C
authors: C
authors: Lacoste
authors: L
authors: L
authors: Ouldamer
authors: G
authors: G
authors: Body
authors: H
authors: H
authors: Marret
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms / Q000601:surgery; D004338:Drug Combinations; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use*; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects* / Q000379:methods; D008210:Lymphocele / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D013917:Thrombin / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C518955:TachoSil; D005340:Fibrinogen; D013917:Thrombin